GLOW

GLOW is a research-chemical blend of three peptides marketed for skin quality and soft-tissue repair. The most common composition is 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 in a single lyophilized 70 mg vial. No published human trial has evaluated this specific combination.

Stack composition is not standardized. The 5:1:1 ratio is the dominant vendor format in 2026, but some sellers offer GLOW with TB-500 swapped for Thymosin Beta-4 full-length, or with AHK-Cu instead of GHK-Cu. Compounds and protocols vary by source. The articles for each individual peptide carry the underlying evidence base, regulatory status, and safety profile.

The three peptides reached the research-chemical market through different routes. GHK-Cu was characterized by Loren Pickart in 1973 as a copper-binding tripeptide present in human plasma at declining concentrations with age. It has been used as a cosmetic ingredient under the INCI name "Copper Tripeptide-1" since the 1990s. BPC-157 was synthesized in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb as a 15-amino-acid fragment of a protein characterized in human gastric juice. TB-500 was developed in the 2000s by RegeneRx as the 17-amino-acid actin-binding domain of thymosin beta-4. Each has a separate development history. The blend itself has no developer of record. It emerged from research-chemical communities and online forums in the mid-2020s.

The Combined Human Evidence

There is none.

A PubMed search for the three peptides combined in any clinical study returns zero records as of May 2026. ClinicalTrials.gov lists no trial evaluating the blend. The marketing claim that the three peptides work synergistically is mechanistic reasoning extrapolated from animal data on each component in isolation. That reasoning may turn out to be correct in humans. It may also turn out to be wrong, as it has for many combinations of compounds that worked alone in rats and failed when stacked in people.

Individual-compound evidence summaries:

• GHK-Cu: in-vitro studies on dermal fibroblasts and ex-vivo skin samples document collagen upregulation, MMP-2 modulation, and wound-edge contraction. Topical cosmetic claim substantiation is robust. Injectable use has no controlled human pharmacokinetic data.
• BPC-157: three small published human studies as of 2026, none placebo-controlled. Several hundred rat studies, most from a single laboratory in Zagreb. A 2025 scoping review flagged the literature for publication bias.
• TB-500: preclinical evidence in animal myocardial infarction and corneal-wound models. No randomized controlled trials in humans. Sits on the FDA Category 2 bulks list.

Regulatory and Legal Status

The blend itself has no regulatory status. Its components do.

FDA. None of the three is FDA-approved for human use as an injectable drug. BPC-157 and TB-500 are both on the FDA Category 2 bulk drug substances list, which prohibits 503A and 503B compounding pharmacies from producing them. The FDA Pharmacy Compounding Advisory Committee will reconsider BPC-157's status at the meeting scheduled for July 23 and 24, 2026. GHK-Cu is approved as a cosmetic ingredient (Copper Tripeptide-1, INCI name) but has no approval as an injectable drug.

Compounding pharmacies. Multi-compound mixtures of unapproved bulk substances are not permitted by US compounding rules. A licensed pharmacy that compounds the GLOW blend for patient use is operating outside the regulatory framework. The blends sold today come from research-chemical suppliers labeled "for research use only, not for human consumption."

EMA. The European Medicines Agency has not approved any of the three components for human use.

WADA. Both BPC-157 and TB-500 appear on the 2026 WADA Prohibited List under Section S0 (Non-Approved Substances). GHK-Cu is not listed.

This compound is on the World Anti-Doping Agency (WADA) Prohibited List. Use in competitive sport, in-competition or out-of-competition, constitutes an anti-doping rule violation.

The three peptides target different phases of tissue repair. Vendors describe this as synergy. The pharmacological evidence for synergy is mechanistic, not empirical.

GHK-Cu is a tripeptide (glycyl-L-histidyl-L-lysine) that binds copper(II) at a 1:1 stoichiometry. The copper complex modulates gene expression in fibroblasts. A 2018 review by Pickart and Margolina cataloged the effects: upregulation of collagen and elastin synthesis, increased decorin expression, modulation of metalloproteinases (MMP-2 stimulation, MMP-1 reduction in some contexts), and antioxidant signaling through SOD activation. Most of this data comes from cultured human dermal fibroblasts and ex-vivo human skin biopsies. Injected systemic activity has not been characterized in published human studies.

BPC-157 has no defined receptor. The proposed primary mechanism is pro-angiogenic activity through upregulation of VEGFR2 in animal injury models, plus modulation of the nitric oxide system. Rat studies report acceleration of tendon, ligament, gut, and corneal wound healing across more than two decades of work, most of it from the Sikiric group. Human pharmacokinetic data is not published.

TB-500 is the active fragment of thymosin beta-4. It binds G-actin and sequesters monomeric actin, which influences cell migration and cytoskeletal reorganization. Preclinical evidence reports faster cell migration into wound beds and increased corneal re-epithelialization in rabbit models. A 2025 review by Mao and colleagues summarizes the beta-thymosin family and notes the gap between animal data and confirmed human trials.

The combination rationale is sequential: BPC-157 drives angiogenic support, TB-500 mobilizes repair cells, GHK-Cu remodels the extracellular matrix. Whether the three actually act in coordinated phases when co-injected, or whether they simply share an injection site without functional synergy, is not known. No published study has measured tissue levels of any component after blend injection in humans.

User reports in research-chemical communities describe accelerated skin recovery, faster resolution of soft-tissue injuries, improved hair quality, and reduced visible signs of skin aging. These reports are anecdotal. They are not controlled, not blinded, and not standardized for dose, route, or duration.

Animal data supports parts of the user-claim picture in isolation. Rat studies on BPC-157 report faster tendon and gut healing. Cell-culture studies on GHK-Cu report collagen upregulation. Animal corneal-wound studies on TB-500 report faster re-epithelialization. None of these endpoints has been measured in a human trial of the blend.

The most honest summary: each component has a plausible mechanistic story. The story has not been tested in humans, alone or in combination. Reports of efficacy in skin and soft-tissue repair from blend users are real reports but constitute the weakest tier of evidence (uncontrolled anecdote) in clinical research.

No standardized human dosing protocol exists for the GLOW blend. The schedules circulating in research-chemical communities are extrapolated from individual-compound off-label use and are not supported by published human pharmacokinetic data.

The most common pre-blend vendor format is 70 mg total in a single lyophilized vial (50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500). Community-circulated reconstitution protocols typically use 3 mL of bacteriostatic water, giving approximately 23.3 mg per mL of total blend. The protocol-published dose per injection is then 10 to 30 units on a U-100 insulin syringe, daily, for 4 to 8 weeks. This corresponds to roughly 2.3 to 7.0 mg of total blend per injection.

These numbers come from off-label adult research-use protocols and are reported here as descriptive only. No controlled pharmacokinetic study supports a specific dose, frequency, or cycle for the blend. Pharmacy compounding rules in the US prohibit the production of multi-compound mixtures of unapproved bulks for human use, meaning every vial of GLOW on the market today is a research-chemical product sold under "not for human consumption" labeling.

The blend itself has no published safety database. Adverse events have to be inferred from the individual-compound profiles, with the additional caveat that combination effects (drug-drug interactions, additive toxicity, or unmasking of effects that did not appear with single agents) are not documented.

GHK-Cu is generally well tolerated topically. Injectable safety data is limited. Possible concerns include localized skin reactions at injection sites, transient erythema, and theoretical copper accumulation with chronic high-dose use.

BPC-157 animal studies have not flagged dose-limiting toxicity. Two published human pilots and one IV safety study in two adults reported no serious adverse events at the doses tested. Long-term human safety data does not exist. A 2025 commentary in Pharmaceuticals flagged mechanistic concerns about pro-angiogenic activity supporting tumor vascularization in patients with undiagnosed malignancy, and about nitric oxide system stimulation at sustained high doses.

TB-500 has no published human safety trials beyond the original RegeneRx development program for corneal indications, which used topical formulations. Injectable safety data is preclinical only. Long-term human safety data does not exist.

Blend-specific risks. Reconstitution of a multi-compound vial introduces variables that single-compound vials do not. Vendor blends carry the combined endotoxin risk of the three component manufacturers and the cumulative purity risk of all three peptides. Injection-site reactions, infection risk at sub-cutaneous administration sites, and the cardiovascular effects of repeated injection of a copper complex have not been quantified in any human study.

GLOW is one of several research-chemical "blends" marketed for combined healing and skin claims. The closest peer is KLOW, which adds KPV and Larazotide to extend the gut-barrier and immune-modulation claims. The Wolverine Stack pairs BPC-157 and TB-500 without GHK-Cu and is marketed purely for soft-tissue recovery rather than skin endpoints.

The mechanistic rationale for GLOW makes more sense than the empirical evidence supports. Angiogenesis, cell migration, and collagen remodeling are three real phases of tissue repair, and the three peptides have plausible activity at each phase in animal models. What is missing is any controlled human trial showing the phases align temporally when the peptides are co-injected, or that the combined effect exceeds what any single component achieves alone. That data does not exist. Anyone evaluating GLOW should weigh the strong mechanistic story against the empty human evidence column.

For practical purposes, GLOW shares the regulatory profile of its components. Two of the three are WADA-prohibited and on the FDA Category 2 bulks list. The blend is not produced by licensed compounding pharmacies in the US. Use sits outside the medical regulatory framework.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.